NO324815B1 - Anvendelse av et TNF-beta-lignende protein, eller et DNA- eller RNA molekyl som koder for det samme, for fremstilling av et preparat for behandling av androgen-uavhengig prostatacancer - Google Patents

Anvendelse av et TNF-beta-lignende protein, eller et DNA- eller RNA molekyl som koder for det samme, for fremstilling av et preparat for behandling av androgen-uavhengig prostatacancer Download PDF

Info

Publication number: NO324815B1
Authority: NO; Norway
Prior art keywords: androgen; prostate cancer; preparation; protein; cells
Prior art date: 1996-09-11

Application number

NO19991161A

Other languages

English (en)

Norwegian (no)

Other versions

NO991161D0 (no

NO991161L (no

Inventor

Mark Erlander

Shaoming Huang

Michael Jackson

Per Peterson

Original Assignee

Ortho Mcneil Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-11

Filing date

1999-03-10

Publication date

2007-12-10

1999-03-10 Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc

1999-03-10 Publication of NO991161D0 publication Critical patent/NO991161D0/no

1999-05-07 Publication of NO991161L publication Critical patent/NO991161L/no

2007-12-10 Publication of NO324815B1 publication Critical patent/NO324815B1/no

Links

239000003098 androgen Substances 0.000 title claims abstract description 46
206010060862 Prostate cancer Diseases 0.000 title claims abstract description 40
208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 39
238000002360 preparation method Methods 0.000 title claims description 19
108090000623 proteins and genes Proteins 0.000 title abstract description 54
102000004169 proteins and genes Human genes 0.000 title abstract description 48
150000007523 nucleic acids Chemical class 0.000 claims abstract description 9
231100000331 toxic Toxicity 0.000 claims abstract description 7
230000002588 toxic effect Effects 0.000 claims abstract description 7
238000001415 gene therapy Methods 0.000 claims abstract description 6
125000003275 alpha amino acid group Chemical group 0.000 claims description 17
108020004414 DNA Proteins 0.000 claims description 11
239000013598 vector Substances 0.000 claims description 10
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 8
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 8
230000004071 biological effect Effects 0.000 claims description 7
108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
238000000034 method Methods 0.000 abstract description 17
230000035755 proliferation Effects 0.000 abstract description 12
108020004707 nucleic acids Proteins 0.000 abstract description 5
102000039446 nucleic acids Human genes 0.000 abstract description 5
239000000203 mixture Substances 0.000 abstract description 3
239000008194 pharmaceutical composition Substances 0.000 abstract description 2
210000004027 cell Anatomy 0.000 description 79
235000018102 proteins Nutrition 0.000 description 44
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 16
239000002299 complementary DNA Substances 0.000 description 16
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
230000004663 cell proliferation Effects 0.000 description 9
230000000694 effects Effects 0.000 description 9
238000000338 in vitro Methods 0.000 description 9
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 8
102100037850 Interferon gamma Human genes 0.000 description 8
108010074328 Interferon-gamma Proteins 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 8
239000012091 fetal bovine serum Substances 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
229940104230 thymidine Drugs 0.000 description 8
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
229960000485 methotrexate Drugs 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
238000010348 incorporation Methods 0.000 description 6
238000011534 incubation Methods 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
210000002307 prostate Anatomy 0.000 description 6
210000004899 c-terminal region Anatomy 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000012528 membrane Substances 0.000 description 5
238000000746 purification Methods 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
108091026890 Coding region Proteins 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000003636 conditioned culture medium Substances 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
238000001262 western blot Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
229940030486 androgens Drugs 0.000 description 3
238000010276 construction Methods 0.000 description 3
239000008121 dextrose Substances 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
239000012535 impurity Substances 0.000 description 3
238000004949 mass spectrometry Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
239000000523 sample Substances 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
230000036962 time dependent Effects 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
108010039627 Aprotinin Proteins 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
241001460678 Napo <wasp> Species 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
102100038358 Prostate-specific antigen Human genes 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
108091034057 RNA (poly(A)) Proteins 0.000 description 2
108091085018 TGF-beta family Proteins 0.000 description 2
102000043168 TGF-beta family Human genes 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000001919 adrenal effect Effects 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
229960004405 aprotinin Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
230000030833 cell death Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
230000003902 lesion Effects 0.000 description 2
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
108010052968 leupeptin Proteins 0.000 description 2
230000001394 metastastic effect Effects 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
125000001360 methionine group Chemical class N[C@@H](CCSC)C(=O)* 0.000 description 2
239000007758 minimum essential medium Substances 0.000 description 2
239000012457 nonaqueous media Substances 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
229950000964 pepstatin Drugs 0.000 description 2
108010091212 pepstatin Proteins 0.000 description 2
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
210000002826 placenta Anatomy 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
201000001514 prostate carcinoma Diseases 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
239000013017 sartobind Substances 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
239000000243 solution Substances 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000001890 transfection Methods 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
PQMRRAQXKWFYQN-UHFFFAOYSA-N 1-phenyl-2-sulfanylideneimidazolidin-4-one Chemical compound S=C1NC(=O)CN1C1=CC=CC=C1 PQMRRAQXKWFYQN-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
102000005606 Activins Human genes 0.000 description 1
108010059616 Activins Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
239000012619 Butyl Sepharose® Substances 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
108700003483 Drosophila dpp Proteins 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
101500025624 Homo sapiens Transforming growth factor beta-2 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
102000002746 Inhibins Human genes 0.000 description 1
108010004250 Inhibins Proteins 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
241000713869 Moloney murine leukemia virus Species 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101100278853 Mus musculus Dhfr gene Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241000282339 Mustela Species 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
230000004989 O-glycosylation Effects 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
241001505332 Polyomavirus sp. Species 0.000 description 1
241000288906 Primates Species 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000724205 Rice stripe tenuivirus Species 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
241000710961 Semliki Forest virus Species 0.000 description 1
108091081021 Sense strand Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
108010055044 Tetanus Toxin Proteins 0.000 description 1
102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
239000000488 activin Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
230000019552 anatomical structure morphogenesis Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
239000013602 bacteriophage vector Substances 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
239000013601 cosmid vector Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000012010 growth Effects 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
239000000893 inhibin Substances 0.000 description 1
239000003999 initiator Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
-1 lactated Tinger's Substances 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
208000023958 prostate neoplasm Diseases 0.000 description 1
238000011472 radical prostatectomy Methods 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000005287 template synthesis Methods 0.000 description 1
229940118376 tetanus toxin Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000025366 tissue development Effects 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Toxicology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO19991161A 1996-09-11 1999-03-10 Anvendelse av et TNF-beta-lignende protein, eller et DNA- eller RNA molekyl som koder for det samme, for fremstilling av et preparat for behandling av androgen-uavhengig prostatacancer NO324815B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2592396P	1996-09-11	1996-09-11
PCT/US1997/016191 WO1998011224A1 (en)	1996-09-11	1997-09-11	Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods

Publications (3)

Publication Number	Publication Date
NO991161D0 NO991161D0 (no)	1999-03-10
NO991161L NO991161L (no)	1999-05-07
NO324815B1 true NO324815B1 (no)	2007-12-10

Family

ID=21828810

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19991161A NO324815B1 (no)	1996-09-11	1999-03-10	Anvendelse av et TNF-beta-lignende protein, eller et DNA- eller RNA molekyl som koder for det samme, for fremstilling av et preparat for behandling av androgen-uavhengig prostatacancer

Country Status (12)

Country	Link
US (1)	US6107476A (pt)
EP (1)	EP0950105A1 (pt)
JP (1)	JP2001500732A (pt)
KR (1)	KR20000038040A (pt)
CN (1)	CN1233289A (pt)
AU (1)	AU735776B2 (pt)
BR (1)	BR9711763A (pt)
CA (1)	CA2265444C (pt)
IL (2)	IL128872A0 (pt)
NO (1)	NO324815B1 (pt)
NZ (1)	NZ334592A (pt)
WO (1)	WO1998011224A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5994102A (en) *	1994-12-15	1999-11-30	Human Genome Sciences, Inc.	Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US6521227B1 (en)	1999-11-18	2003-02-18	Peter L. Hudson	Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US6524802B1 (en) *	1996-03-29	2003-02-25	The Johns Hopkins University School Of Medicine	Methods of detecting growth differentiation factor-14
US6465181B2 (en) *	1999-03-25	2002-10-15	Abbott Laboratories	Reagents and methods useful for detecting diseases of the prostate
DE60032355T2 (de) *	1999-05-17	2007-04-26	Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh	NEUROPROTEKTIVE EIGENSCHAFTEN VON GDF-15, EINEM VERTRETER DER TGF-ß-SUPERFAMILIE
US7141661B2 (en)	2000-09-08	2006-11-28	The United States Of America As Represented By The Department Of Health And Human Services	Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
US20070154889A1 (en) *	2004-06-25	2007-07-05	Veridex, Llc	Methods and reagents for the detection of melanoma
US20070237713A1 (en) *	2006-04-04	2007-10-11	Fan Rong A	PCan065 Antibody Compositions and Methods of Use
US9550819B2 (en)	2012-03-27	2017-01-24	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
CA2899170C (en)	2013-01-30	2022-08-02	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use in treating metabolic disorders
US9161966B2 (en)	2013-01-30	2015-10-20	Ngm Biopharmaceuticals, Inc.	GDF15 mutein polypeptides
US10588980B2 (en)	2014-06-23	2020-03-17	Novartis Ag	Fatty acids and their use in conjugation to biomolecules
SG11201700378PA (en)	2014-07-30	2017-02-27	Ngm Biopharmaceuticals Inc	Compositions and methods of use for treating metabolic disorders
DK3212226T3 (da)	2014-10-31	2020-06-15	Ngm Biopharmaceuticals Inc	Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser
SG11201807279QA (en)	2016-03-31	2018-09-27	Ngm Biopharmaceuticals Inc	Binding proteins and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4886747A (en) *	1985-03-22	1989-12-12	Genentech, Inc.	Nucleic acid encoding TGF-β and its uses
CA1340740C (en) *	1987-12-08	1999-09-14	Eileen R. Mulvihill	Co-expression in eukaryotic cells
JPH07250688A (ja) *	1994-01-28	1995-10-03	Sagami Chem Res Center	ＴＧＦ−βスーパーファミリー蛋白質をコードするヒト新規ｃＤＮＡ
JPH07258293A (ja) *	1994-03-23	1995-10-09	Asahi Chem Ind Co Ltd	新規な蛋白質ならびにその製造方法
AU1830195A (en) *	1994-12-15	1996-07-03	Human Genome Sciences, Inc.	Prostatic growth factor
AU711368B2 (en) *	1995-06-22	1999-10-14	St Vincent's Hospital Sydney Limited	Novel TGF-beta like cytokine
EP0833912B1 (en) *	1995-06-22	2009-02-25	St Vincent's Hospital Sydney Limited	Novel tgf-beta like cytokine
US6524802B1 (en) *	1996-03-29	2003-02-25	The Johns Hopkins University School Of Medicine	Methods of detecting growth differentiation factor-14

1997
- 1997-09-11 BR BR9711763A patent/BR9711763A/pt not_active Application Discontinuation
- 1997-09-11 US US08/927,433 patent/US6107476A/en not_active Expired - Lifetime
- 1997-09-11 NZ NZ334592A patent/NZ334592A/xx not_active IP Right Cessation
- 1997-09-11 JP JP10513906A patent/JP2001500732A/ja active Pending
- 1997-09-11 CA CA002265444A patent/CA2265444C/en not_active Expired - Lifetime
- 1997-09-11 AU AU43442/97A patent/AU735776B2/en not_active Expired
- 1997-09-11 CN CN97197712A patent/CN1233289A/zh active Pending
- 1997-09-11 EP EP97941557A patent/EP0950105A1/en not_active Withdrawn
- 1997-09-11 WO PCT/US1997/016191 patent/WO1998011224A1/en not_active Ceased
- 1997-09-11 KR KR1019990701981A patent/KR20000038040A/ko not_active Ceased
- 1997-09-11 IL IL12887297A patent/IL128872A0/xx unknown
1999
- 1999-03-08 IL IL128872A patent/IL128872A/en not_active IP Right Cessation
- 1999-03-10 NO NO19991161A patent/NO324815B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN1233289A (zh)	1999-10-27
IL128872A0 (en)	2000-01-31
AU735776B2 (en)	2001-07-12
WO1998011224A1 (en)	1998-03-19
JP2001500732A (ja)	2001-01-23
EP0950105A1 (en)	1999-10-20
IL128872A (en)	2009-08-03
AU4344297A (en)	1998-04-02
NZ334592A (en)	2000-10-27
BR9711763A (pt)	1999-08-24
KR20000038040A (ko)	2000-07-05
CA2265444A1 (en)	1998-03-19
NO991161D0 (no)	1999-03-10
US6107476A (en)	2000-08-22
NO991161L (no)	1999-05-07
CA2265444C (en)	2008-11-18

Publication	Publication Date	Title
EP3072519B1 (en)	2020-08-19	Peptide having angiogenesis inhibitory activity and composition containing same
AU741856B2 (en)	2001-12-13	Vascular endothelial growth factor-B
EP1767546B1 (en)	2012-03-07	Angiogenesis-inhibiting chimeric protein and the use
NO324815B1 (no)	2007-12-10	Anvendelse av et TNF-beta-lignende protein, eller et DNA- eller RNA molekyl som koder for det samme, for fremstilling av et preparat for behandling av androgen-uavhengig prostatacancer
AU753889B2 (en)	2002-10-31	Methods of producing anti-angiogenic proteins: endostatin, angiostatin or restin, using a pichia yeast expression system
RU2430162C2 (ru)	2011-09-27	Варианты эритропоэтина
CA2465953A1 (en)	2003-05-15	Novel isoforms of vascular endothelial cell growth inhibitor
AU2002359446A1 (en)	2003-07-24	Novel isoforms of vascular endothelial cell growth inhibitor
Van Leuven et al.	1992	The primary sequence and the subunit structure of mouse α‐2‐macroglobulin, deduced from protein sequencing of the isolated subunits and from molecular cloning of the cDNA
US20110008363A1 (en)	2011-01-13	Erythropoietin variants
US6797488B1 (en)	2004-09-28	Methods of producing anti-angiogenic proteins
US20040059098A1 (en)	2004-03-25	Egf motif protein, egfl6 materials and methods
Tejada et al.	1995	Cloning of an avian antithrombin: developmental and hormonal regulation of expression
WO2009116529A1 (ja)	2009-09-24	ポリペプチドおよび当該ポリペプチドを含む医薬組成物
CN100480264C (zh)	2009-04-22	一种广谱抑制癌细胞生长的蚯蚓蛋白及其编码序列
KR101590959B1 (ko)	2016-02-02	육량체 형성 도메인과 결합된 trail 융합 단백질 및 이를 유효성분으로 포함하는 혈관 재협착증 치료용 조성물
CN100443501C (zh)	2008-12-17	人骨髓基质细胞来源的线粒体转运蛋白分子及其编码序列和用途
CN100400658C (zh)	2008-07-09	新型人死亡抵抗蛋白，其编码序列及用途
US6908765B1 (en)	2005-06-21	Polypeptide—human SR splicing factor 52 and a polynucleotide encoding the same
EP1636258A2 (en)	2006-03-22	Angiogenic factor and inhibitors thereof
CN100523189C (zh)	2009-08-05	新型人免疫细胞抑制性受体klrl1的功能及用途
US20030165886A1 (en)	2003-09-04	EGF motif protein, EGFL6 materials and methods
CN1919868B (zh)	2011-09-21	慢性神经痛相关蛋白及其基因
EP1228213A2 (en)	2002-08-07	Protein having activity as an angiogenesis modulator
KR20160140147A (ko)	2016-12-07	심장 허혈후 재관류 손상에 의한 심장 질환 치료 및 예방용 조성물

Legal Events

Date	Code	Title	Description
2017-10-09	MK1K	Patent expired